FY2025 · ended Dec 31, 2025 · Revenue $90,000, +11.1% YoY · Filed Mar 30, 2026
Actinium Pharmaceuticals, Inc. (ATNM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $90,000 and a net loss of $33.9 million. Free cash flow was -$24.7 million. As of Jun 30, 2026 it held $36.5 million in cash and investments and $1.3 million in total debt.
Revenue
$90,000
+11.1% vs prior year
Net income (TTM)
$11.31M
+127.6% vs year-ago TTM
Operating cash flow (TTM)
$-22.66M
+26.2% vs year-ago TTM
Free cash flow (TTM)
$-23.24M
EPS (TTM)
$0.36
+127.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.37M
+0.6% vs prior year
Net cash
$35.13M
as of Jun 30, 2026
Operating margin
-40274.4%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATNM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1388320
- Former names
- Cactus Ventures, Inc. (until Mar 29, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $90,000 | — | $81,000 | $1.0M | $1.1M |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$25.0M |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M | -$24.8M |
| Diluted EPS | -$1.09 | -$1.27 | -$1.83 | -$1.37 | — |
| Operating cash flow | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M |
| Free cash flow | -$24.7M | -$33.1M | -$47.5M | $8.3M | -$21.0M |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M |
| Stockholders' equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M |
| Cash and investments | $48.0M | $72.9M | $76.7M | $108.9M | $77.8M |
| Total debt | $1.7M | $1.6M | $2.1M | $498,000 | $310,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Aug 14, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
May 29, 2026 | May 27, 2026 |
All 511 Actinium Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.